Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
01 1Cayman Pharma s r.o.
02 1Chirogate International Inc
03 1EUROAPI Hungary Ltd.
04 1MSN Laboratories Private Limited
05 1Pharmacia and Upjohn Company LLC
06 1SUN PHARMACEUTICAL INDUSTRIES, INC.
07 1Sai Life Sciences Limited
08 1Wasserburger Arzneimittelwerk GmbH
01 1Epoprostenol
02 6Epoprostenol Sodium
03 1Epoprostenol sodium
01 1Czech Republic
02 1France
03 3India
04 1Sweden
05 1Taiwan
06 1U.S.A
Cayman Pharma is Europe's most reliable and versatile source for Prostaglandin APIs//FDA approved.
NDC Package Code : 61556-030
Start Marketing Date : 2011-04-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
Chirogate is a professional Prostaglandin manufacturer.
NDC Package Code : 68245-0005
Start Marketing Date : 2005-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.
NDC Package Code : 82231-106
Start Marketing Date : 2014-10-28
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0004
Start Marketing Date : 2011-09-21
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0009-5164
Start Marketing Date : 2014-07-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62287-123
Start Marketing Date : 2010-04-22
End Marketing Date : 2025-12-31
Dosage Form (Strength) : INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION (1.5mg/10mL)
Marketing Category : DRUG FOR FURTHER PROCESSING
NDC Package Code : 14474-025
Start Marketing Date : 2012-10-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62756-033
Start Marketing Date : 2021-01-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
A Epoprostenol Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Epoprostenol Sodium, including repackagers and relabelers. The FDA regulates Epoprostenol Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Epoprostenol Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Epoprostenol Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Epoprostenol Sodium supplier is an individual or a company that provides Epoprostenol Sodium active pharmaceutical ingredient (API) or Epoprostenol Sodium finished formulations upon request. The Epoprostenol Sodium suppliers may include Epoprostenol Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Epoprostenol Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Epoprostenol Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Epoprostenol Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Epoprostenol Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Epoprostenol Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Epoprostenol Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Epoprostenol Sodium suppliers with NDC on PharmaCompass.
We have 8 companies offering Epoprostenol Sodium
Get in contact with the supplier of your choice:
LOOKING FOR A SUPPLIER?
